UpdatesPlus Nicotinic Receptors - Current Research and Development - March 2009
Order a company subscription now and your organization will receive the next 12 monthly issues of UpdatesPlus
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Addiction.
Now we are seeing the field expand with peripheral nicotinic receptors gaining increasing attention in relation to further indications including various inflammatory conditions
Are you involved in these areas; are you developing a nicotinic receptor ligand? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only identifies all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
And there's more...
Smoking cessation remains the one approved indication for the only commercially available selective nicotinic receptor ligand varenicline (Chantix/Champix). There is a considerable overlap between companies interested in nicotinic receptors and smoking cessation. UpdatesPlus therefore offers a detailed and up to date analysis of activity in the smoking cessation arena
Published monthly along with fully up to date pipelines, UpdatesPlus offers a key insight into strategy and development as well as new research advances. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine. Well over half the companies involved in nicotinic receptors subscribe to UpdatesPlus. To see what you are missing open the free issue below
See February 2008 edition now (free sample copy)
Table of Contents
What's in the March 2009 edition of UpdatesPlus-Nicotinic Receptors?
α7 nicotinic receptors
- α7 receptor agonists as candidate early stage and potentially disease modifying treatments of schizophrenia - α7 receptor agonists have historically been investigated in schizophrenic patients already displaying psychoses. We believe that greater benefit may be gained by evaluating α7 receptor agonists in patients with very early stage, perhaps prodromic, disease. Find out how we believe nicotinic receptors can better meet their potential and generate greater revenue in schizophrenia
- Profile of SEN-12333 published – neuroprotection and procognitive activity demonstrated in Alzheimer’s disease models - SEN-12333 is unlikely to be developed clinically however we believe that its profile is encouraging. Find out all about SEN-12333 here.
- Full and up to date α7 receptor pipeline, all breaking R&D activity and patent activity
α4ß2 nicotinic receptors
- AstraZeneca continues to wait for ADHD data prior to deciding on future of AZD3480 – We provide an update on the development of AZD3480. Where is this candidate going? Has AstraZeneca started to evaluate AZD3480 as an adjunct to Seroquel in patients with resistant depression?
- Targacept to focus on mixed nicotinic receptor ligands for the treatment of pain - As well as partnering with AstraZeneca on the development of AZD-3480, Targacept was developing TC-6499 as candidate analgesics with GSK. Development has ceased. Why? What is the future of nicotinic ligands as analgesics?
- Vascular dementia emerges as a potential indication for α4β2 receptor agonists - The development of nicotinic ligands has previously focussed on Alzheimer's disease however it is likely that the potential of α4β2 receptor agonists may extend across the dementia spectrum. Read about the latest research to support this.
- Full and up to date α4β2 receptor pipeline, all breaking R&D activity and patent activity
Other nicotinic receptors
- α5 receptor antagonists as candidate treatments of premenstrual dysphoric disorder (PMDD) - We believe that PMDD could be an excellent target for α5 receptor antagonists. The indication is unmet and could be worth upwards of $0.25 billion/year. If your company is involved in women's health, α5 receptors may be your next target.
Smoking cessation - Nicotine addiction
- Data argues against varenicline worsening depression - New data should be welcomed by Pfizer
- Varenicline reduces alcohol consumption in smokers - A new study has been published suggesting that varenicline may be of benefit to heavy drinkers as well as smokers. Curiously Pfizer has been relatively quiet with respect to this life cycle possibility
- Nabi’s NicVax represents an interesting licensing option for companies developing nicotinic smoking cessation products - Nabi had a rough ride at its most recent investor presentation. We believe that NicVax could represent an interesting licensing option especially for companies developing nicotinic receptor ligands
- Novartis finally opens phase 2 study of NIC002
- Full and up to date pipeline of smoking cessation therapeutics
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September
- October
- November
- December
2009 issues:
- January 2009
- February 2009
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors MEM 63908 R4996 ABT-107 TC-5619 EVP-6124 AZD-0328 SSR-180711 gts-21 MEM 3454 R3487 TC-6499 abt-560 AZD3480 TC-1734 tc-5214 ispronicline abt-894 ABT-089 nicotinic receptors cognition cognitive cias amyloid depression smoking cessation alpha7 alpha6 alpha4beta2 adhd memory nicotinic receptors varenicline champix chantix wellbutrin nicotinic receptor neuronal receptors abt894 schizophrenia ssr180711 nicotine nicotinic receptors alzheimers abt nicvax nic002 quitpak Niccine evt 302 Niquitin Targacept gsk abbott cytos nabi novartis Celtic Pharma pfizer evotec NeuroSearch servier siena wyeth roche nicotinic receptor receptors nicotine 2009 depression schizophrenia research roche nicvax
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.